{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "92 (mean age 69 years; 50% male) met our inclusion criteria"
      },
      "Intervention": {
        "score": 1,
        "evidence": "assessing potential predictive variables for mortality in the EVT-treated patients"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was death within 90 days."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of the 182 patients in the DEFUSE 3 study"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "92 (mean age 69 years; 50% male) met our inclusion criteria"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "2/52 (3.9%), 3/23 (13.0%), and 9/17 (52.9%) of patients died, respectively (P<0.001)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 8,
    "max_score": 25
  },
  "model": "gpt-4o"
}